TRANSGENE (EPA:TNG) | WebDisclosure

BRIEF

published on 01/21/2025 at 17:50, 1 year 2 months ago

Transgene Prepares for Biomed Investor Forum

Investors BIOMED Forum Immunotherapy Transgene Viral Vectors
BRIEF

published on 01/21/2025 at 17:50, 1 year 2 months ago

Transgene se prépare pour le Biomed Forum des investisseurs

Investisseurs BIOMED Forum Immunothérapie Transgene Vecteurs Viraux
PRESS RELEASE

published on 01/21/2025 at 17:45, 1 year 2 months ago

Transgene to Participate in the Biomed Forum Investor Conference
Transgene's management team to participate in the Biomed Forum Investor Conference in Paris on February 4, 2025

Investor Conference Paris BIOMED Forum Transgene February 4
PRESS RELEASE

published on 01/21/2025 at 17:45, 1 year 2 months ago

Transgene participera à la conférence investisseurs Biomed Forum
Transgene participera à la conférence investisseurs Biomed Forum le 4 février 2025. Présentation de ses immunothérapies contre le cancer reposant sur des vecteurs viraux

BIOMED Forum Immunothérapie Cancer Transgene Vecteurs Viraux
BRIEF

published on 11/05/2024 at 07:35, 1 year 4 months ago

Transgene and ProBioGen join forces for personalized cancer vaccines

Biotechnology Cancer Transgene ProBioGen Personalized Vaccines
BRIEF

published on 11/05/2024 at 07:35, 1 year 4 months ago

Transgene et ProBioGen unissent leurs forces pour les vaccins anti-cancer personnalisés

Biotechnologie Cancer Transgene ProBioGen Vaccins Personnalisés
PRESS RELEASE

published on 11/05/2024 at 07:30, 1 year 4 months ago

Transgene et ProBioGen collaborent pour faire progresser le développement des vaccins thérapeutiques individualisés
Transgene et ProBioGen collaborent pour développer les vaccins thérapeutiques individualisés, annoncent un accord de licence pour la lignée cellulaire AGE1.CR.pIX®

Transgene Vaccins ProBioGen Thérapeutiques Lignée Cellulaire
PRESS RELEASE

published on 10/14/2024 at 07:30, 1 year 5 months ago

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
PRESS RELEASE

published on 10/14/2024 at 07:30, 1 year 5 months ago

Transgene fait le point sur l’étude de Phase II du vaccin thérapeutique TG4001 dans les cancers du col de l’utérus et anogénitaux HPV16 positifs, récurrents ou métastatiques
Transgene présente les résultats préliminaires de l'étude de Phase II du vaccin TG4001 dans les cancers du col de l'utérus HPV16 positifs, montrant une tendance positive malgré le non-atteinte de l'objectif principal

Transgene Vaccin Thérapeutique Étude De Phase II Cancer Du Col De L'utérus HPV16
BRIEF

published on 09/14/2024 at 09:10, 1 year 6 months ago

Transgene and BioInvent: promising results for the oncolytic virus BT-001

Cancer Transgene Oncolytic Virus BioInvent BT-001

Published on 03/26/2026 at 23:00, 5 hours 38 minutes ago

FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 6 hours 33 minutes ago

BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 6 hours 38 minutes ago

Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 6 hours 38 minutes ago

Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 7 hours 38 minutes ago

Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity

View all ACCESSWIRE

Published on 03/27/2026 at 04:00, 38 minutes ago

Tech-Driven Restoration: Saving the World's Critically Endangered White-headed Langur
Published on 03/26/2026 at 20:48, 7 hours 50 minutes ago

Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 9 hours 18 minutes ago

Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:13, 9 hours 25 minutes ago

Director Declaration
Published on 03/26/2026 at 19:09, 9 hours 29 minutes ago

2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)

View all EQS

Published on 03/26/2026 at 18:17, 10 hours 21 minutes ago

Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 10 hours 21 minutes ago

Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 10 hours 38 minutes ago

Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 10 hours 38 minutes ago

Calendrier financier 2026
Published on 03/26/2026 at 18:00, 10 hours 38 minutes ago

LABORATOIRES EUROMEDIS - Fin du contrat de liquidité

View all LES ECHOS COMFI WIRE

News